Pharmaceutical giant AstraZeneca (AZN) is expanding its weight-loss and diabetes drug portfolio in a deal with China’s CSPC. In total, the two firms have agreed to develop eight treatments including a ‘clinical-ready’ asset. Share price: £134.50 (unch) PE: 30.9x Market cap: £208bn Yield: 1.8% NEXT-GENERATION TREATMENTS Astra has agreed a deal with CSPC to develop … Continue reading AstraZeneca expands weight-loss portfolio with CSPC deal